Dual-target TQB2102 breast cancer drug secures clinical testing for India

The Takeaway

• Early reports indicate the eight-cycle TQB2102 regimen achieved a 73.1 percent complete response rate during phase two trials.
• The biological architecture relies on an enzyme-cleavable linker to deliver a topoisomerase I inhibitor payload directly into cancer cells.
• Published clinical data shows a manageable safety profile with an average 27.9 percent incidence of severe adverse events.
• The experimental therapy already holds three separate Breakthrough Therapy Designations from Chinese medical authorities.

Cipla Limited holds the exclusive rights to commercialise this experimental oncology treatment across India, South Africa, and five other emerging markets. The pharmaceutical company signed a supply agreement with Chia Tai Tianqing Pharmaceutical Group. This specific manufacturing partner operates as a key subsidiary of the Hong Kong-listed Sino Biopharmaceutical Limited group. They will continue producing the medication throughout all upcoming development phases. The Indian firm takes full control of local clinical trials and medical affairs to secure market access.

Medical professionals administer Rolditamig Deuderuxtecan through an intravenous infusion every three weeks. Researchers tested multiple dosage cohorts during earlier clinical stages. Patients received either 6.0 mg/kg or 7.5 mg/kg regimens over six or eight treatment cycles. A comprehensive phase three trial is currently underway. This broader study will directly compare the medication against standard chemotherapy combinations for patients with HER2-positive breast cancer.

Most conventional antibody-drug conjugates recognise a single binding site on a cancer cell. This treatment utilises a bispecific design instead. It binds to two distinct, non-overlapping epitopes on the HER2 protein simultaneously. The dual-targeting mechanism specifically attacks both the trastuzumab and pertuzumab sites. This simultaneous binding heavily increases the overall anti-tumour activity compared to older single-target approaches.

TQB2102 licensing and development details

Breast cancer continues to pose a significant healthcare challenge for Indian patients. The foundational clinical evidence for this therapy currently stems entirely from multicentre trials conducted in China. The domestic operator must now carefully replicate these safety and efficacy benchmarks locally. Regulators require strict adherence to regional guidelines before granting market access. The company is actively building its domestic healthcare portfolio, recently showing how Testing your lungs no longer requires a painful deep breath with new diagnostic tools. Expanding into advanced oncology treatments marks the next major step in that strategy.

The Unboxed Truth

We track complex medical launches closely at Unbox Daily HQ, and TQB2102 represents a serious shift in oncology targeting. You are looking at a therapy that physically redesigns how cancer drugs attach to proteins. The bispecific approach solves a major limitation of older treatments by hitting the cancer cell from two sides at once. The real hurdle now lies entirely in the clinical pipeline. The local pharmaceutical partner has to prove these foreign trial results hold up in domestic populations. This treatment will not reach your hospital anytime soon.

Best for: Expanding treatment options for patients with advanced HER2-expressing solid tumours.

Who Is This For: Oncology patients aged 40 to 65.

Courtesy: Cipla Limited